All In Biotech

Drug Trial Radar · NCT02795676

Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function

A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta

Last checked: Nov 20, 2026Latest source record: Sep 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

78

Actual

Start

Jun 2016

Primary completion

Oct 2021

Study completion Jul 2022

Sponsor

Lead sponsor
ProtalixIndustry
Sponsor type
Industry
Collaborators
Chiesi Farmaceutici S.p.A.
First posted
Jun 10, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a randomized, double-blind, active control study of the enzyme replacement therapy (ERT) drug PRX-102 (pegunigalsidase alfa) in Fabry disease patients with impaired renal function. Patients who had been treated for approximately 1 year with agalsidase beta and who had been on a stable dose of that product for at least 6 months were randomized in a 2:1 ratio to either switch to PRX-102 or to continue treatment with agalsidase beta. Both treatments were delivered by intravenous infusions every two weeks, at a dosage of 1 mg/kg.

Conditions

  • Fabry Disease

Interventions

  • PRX-102 (pegunigalsidase alfa)Biological

    PRX-102 1 mg/kg every 2 weeks

  • agalsidase betaBiological

    agalsidase beta 1 mg/kg every 2 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Change (Slope) in Estimated Glomerular Filtration Rate (eGFR)Time frame: 24 months

Locations

29 sites in 12 countries. Site status is shown where the registry gives one.

  • UAB Medicine

    Birmingham, Alabama

  • Phoenix Children's Hospital

    Phoenix, Arizona

  • University of California Irvine Center

    Orange, California

  • University of California San Diego

    San Diego, California

  • Emory University School of Medicine

    Atlanta, Georgia

  • University of Iowa Hosptials and Clinics

    Iowa City, Iowa

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Infusion Associates

    Grand Rapids, Michigan

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania

  • Institute of Metabolic Disease, Baylor Healthcare

    Dallas, Texas

  • Renal Disease Research Institute, LLC - Dallas

    Dallas, Texas

  • Eccles Primary Children's Outpatient Services Building

    Salt Lake City, Utah

  • O+O Alpan LLC

    Fairfax, Virginia

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Vseobecna fakultni nemocnice v Praze

    Prague, Czech Republic, Czechia

  • Turku University Central Hospital

    Turku, Finland

  • Hôpital Raymond Poincaré

    Paris, France

  • Semmelweis Egyetem

    Budapest, Hungary

  • Azienda Ospedaliera Universitaria "Federico II"

    Naples, Italy

  • Academisch Medisch Centrum

    Amsterdam, Netherlands

  • Haukeland University Hospital Klinisk Forskningspost

    Bergen, Norway

  • General Hospital Slovenj Gradec

    Slovenj Gradec, Slovenia

  • Hospital de Dia Quiron Zaragoza

    Zaragoza, Spain

  • Klinik und Poliklinik für Innere Medizin UniversitätsSpital Zürich

    Zurich, Switzerland

  • Addenbrooke's Hospital

    Cambridge, United Kingdom

  • The Royal Free Hospital

    London, United Kingdom

  • Salford Royal NHS Foundation Trust

    Salford, United Kingdom

  • Institute of Metabolism and Systems Research

    Edgbaston, Birmingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.